4basebio (4BB) Share Price, News & Analysis

Company Overview

4basebio is a specialist life sciences group focused on supplying therapeutic synthetic DNA for gene therapies and gene-based vaccines and providing solutions for effective and safe delivery of DNA/RNA based products to patients. Our focus is the development of high quality, GMP grade synthetic DNA as well as non-viral nanoparticles which can efficiently and safely deliver fully functional genes to patients. These products and technologies are also available for customers and partners with whom we endeavor to combine our capabilities and know-how to develop gene therapy solutions for clinical development and commercialisation.

Key Stats

• Today's Range: 550.25 to 562.50
• 50-Day Range: 450 to 568.50
• 52-Week Range: 420 to 820
• Volume: 912 shs
• Average Volume: 1,348 shs
• Market Capitalization: £85.21 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: GBX 1,400
• Consensus Rating: Buy

4basebio Stock Analysis - MarketRank™

4basebio scored higher than 33% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

4basebio has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on no strong buy ratings, 1 buy rating, no hold ratings, and no sell ratings.

Upside Potential

4basebio has a consensus price target of GBX 1,400, representing about 154.4% upside from its current price of GBX 550.25.

Amount of Analyst Coverage

4basebio has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of 4basebio is -5.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of 4basebio is -5.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for 4BB.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

4basebio does not currently pay a dividend.

Dividend Growth

4basebio does not have a long track record of dividend growth.

News and Social Media

• Score: 1.9 / 5
• News Sentiment: 0.10

News Sentiment

4basebio has a news sentiment score of 0.10. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.47 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 8 news articles for 4basebio this week, compared to 1 article on an average week.

Company Ownership

• Score: 0.4 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, 4basebio insiders have not sold or bought any company stock.

Percentage Held by Insiders

12.09% of the stock of 4basebio is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

0.86% of the stock of 4basebio is held by institutions.

Company Calendar

• Last Earnings: 9/28/2026
• Today: 10/03/2026

Industry, Sector and Symbol

• Stock Exchange: LON
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: LON:4BB
• CIK: N/A
• Web: www.4basebio.com
• Phone: 44 1223 967 943
• Fax: N/A
• Employees: 101
• Year Founded: N/A

Price Target and Rating

• Average Price Target for 4basebio: GBX 1,400
• High Price Target: GBX 1,400
• Low Price Target: GBX 1,400
• Potential Upside/Downside: +154.4%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Trailing Twelve Months): GBX (109)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -£9.84 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -231.29%
• Return on Assets: -54.30%

Debt

• Debt-to-Equity Ratio: 201.47
• Current Ratio: 2.73
• Quick Ratio: 3.52

Sales & Book Value

• Annual Sales: £1.69 million
• Price / Sales: 50.33
• Cash Flow: GBX 34.22 per share
• Price / Cash Flow: 16.08
• Book Value: GBX (41) per share
• Price / Book: -13.42

Miscellaneous

• Outstanding Shares: 15,485,000
• Free Float: N/A
• Market Cap: £85.21 million
• Optionable: Not Optionable
• Beta: 1.09